2012 Fiscal Year Final Research Report
Development of a new cancer chemotherapy by using curcumin analogs
| Project/Area Number |
22501041
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IWABUCHI Yoshiharu 東北大学, 大学院・薬学研究科, 教授 (20211766)
UEHARA Yoshihiko 東北大学, 大学院・医学研究科, 教授 (30223499)
OHORI Hisatsugu 東北大学, 医学部附属病院, 助教 (30431555)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | クルクミン / 抗腫瘍活性 / NF-κBシグナル伝達阻害 / がん幹細胞 |
|---|
| Research Abstract |
We have developed 86 types of new curcumin analogs, successfully resulting in getting several analogs with higher anti-cancer potential. These analogs are effective for various cancers including colorectal cancer stem cells. They are shown to be NF-κB inhibitors. In animal models, they were also shown to be effective for some cancers such as gastric cancers and colorectal cancer stem cells. These data indicate that new curcumin analogs have some potential to treat cancers.
|
-
[Journal Article] The curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis2011
Author(s)
Sato, A., Kudo, C., Yamakoshi, H., Uehara, Y., Ohor,i H., Ishioka, C., Iwabuchi, Y. Shibata H.
-
Journal Title
Cancer Science
Volume: 102(5)
Pages: 1045-1051
-
-
-
-
[Journal Article] KSRP/FUBP2 is a binding protein of GO-Y086, a cytotoxic curcumin analogue2010
Author(s)
Yamakoshi, H, Kanoh, N, Kudo, C, Sato, A, Ueda, K, Muroi, M, Kon, S, Satake, M, Ohori, O, Ishioka, C, Oshima, Y, Osada, H, Chiba, N, Shibata H, Iwabuchi, Y.
-
Journal Title
ACS Medicinal Chemistry Letters
Volume: 1(6)
Pages: 273-276
-
[Journal Article] A Phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients
Author(s)
Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H
-
Journal Title
Cancer Chemotherapy and Pharmacology
Volume: (in press)
-
-
-
[Presentation] Phase I study of nanoparticle curcumin, a potential anti-cancer agents with improved bioavailability, for patients with cancer who failed standard chemotherapy2012
Author(s)
Kanai, M., Imaizumi, A., Otsuka, Y., Matsumoto, S., Chiba, T., Nishihira, J., Shibata, H.
Organizer
GAP Annual Conference
Year and Date
20120000
-
[Presentation] ゲムシタビンに抵抗性となった膵癌・胆道癌患者に対するナノ化クルクミン療法の第I相臨床試験2012
Author(s)
金井雅史, 森由希子, 西村貴文, 松本繁巳, 柳原一弘, 千葉勉, 波多野悦朗, 川口義弥, 児玉裕三, 西平順, 大塚和令, 柴田浩行
Organizer
第10回日本臨床腫瘍学会学術集会
Year and Date
20120000
-
-
-
-
-
[Presentation] Novel curcumin analogs have anti-tumor potentials against myeloma cells through the suppression of IRF4/MUM1 function2010
Author(s)
Kudo, C., Yamakoshi, H., Sato, A., Ohori, H., Ishioka, C., Iwabuchi, Y., Shibata, H.
Organizer
第69回日本癌学会学術総会
Year and Date
20100000
-
-
-
-
-
[Patent(Industrial Property Rights)] BIS(ARYLMETHYLIDENE9ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF KI-RAS, ERBB2, C-MYC AND CYCLINE D1,β-CATENIN-DEGRADATING AGENT, P53 EXPRESSION ENHANCER2012
Inventor(s)
Hiroyuki Shibata, Yoshiharu Iwabuchi, Hisatsugu Ohori, Hiroyuki Yamakoshi, Yuichi Kakudo
Industrial Property Rights Holder
National University Corporation Tohoku University
Industrial Property Number
8,178,727
Filing Date
2012-05-15
Overseas
